Resverlogix Corp. (RVX.TO)

CAD 0.04

(-11.11%)

Long Term Debt Summary of Resverlogix Corp.

  • Resverlogix Corp.'s latest annual long term debt in 2022 was - USD , down -100.0% from previous year.
  • Resverlogix Corp.'s latest quarterly long term debt in 2023 Q2 was - USD , down -100.0% from previous quarter.
  • Resverlogix Corp. reported annual long term debt of 442 Thousand USD in 2021, up 1063.16% from previous year.
  • Resverlogix Corp. reported annual long term debt of 38 Thousand USD in 2020, down -96.19% from previous year.
  • Resverlogix Corp. reported quarterly long term debt of - USD for 2023 Q2, down -100.0% from previous quarter.
  • Resverlogix Corp. reported quarterly long term debt of - USD for 2023 Q3, down 0.0% from previous quarter.

Annual Long Term Debt Chart of Resverlogix Corp. (2022 - 2001)

Historical Annual Long Term Debt of Resverlogix Corp. (2022 - 2001)

Year Long Term Debt Long Term Debt Growth
2022 - USD -100.0%
2021 442 Thousand USD 1063.16%
2020 38 Thousand USD -96.19%
2019 997 Thousand USD 625.62%
2018 137.4 Thousand USD 0.0%
2017 - USD 0.0%
2016 - USD -100.0%
2015 47.71 Million USD 6.66%
2014 44.73 Million USD 69.02%
2013 26.46 Million USD -0.71%
2012 26.65 Million USD 0.0%
2011 - USD 0.0%
2010 - USD 0.0%
2009 - USD 0.0%
2008 - USD -100.0%
2007 12.1 Million USD -8.77%
2006 13.26 Million USD 0.0%
2005 - USD 0.0%
2004 - USD -100.0%
2003 23.99 Thousand USD 0.0%
2002 - USD 0.0%
2001 - USD 0.0%

Peer Long Term Debt Comparison of Resverlogix Corp.

Name Long Term Debt Long Term Debt Difference
Appili Therapeutics Inc. 875.2 Thousand CAD 100.0%
Eupraxia Pharmaceuticals Inc. - CAD NaN%
Helix BioPharma Corp. - CAD NaN%
Microbix Biosystems Inc. 6.37 Million CAD 100.0%
Medicenna Therapeutics Corp. - CAD NaN%
Satellos Bioscience Inc. - CAD NaN%
Oncolytics Biotech Inc. 290 Thousand CAD 100.0%
Sernova Corp. - CAD NaN%